Insider Transactions in Q4 2024 at Acrivon Therapeutics, Inc. (ACRV)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2024
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,910
-0.84%
|
$119,460
$6.44 P/Share
|
|
Nov 14
2024
|
Erick Gamelin Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
402
-2.32%
|
$2,814
$7.92 P/Share
|
|
Nov 14
2024
|
Rasmus Holm Jorgensen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-1.37%
|
$2,576
$7.92 P/Share
|
|
Nov 14
2024
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
184
-0.48%
|
$1,288
$7.92 P/Share
|
|
Nov 14
2024
|
Katharine Peterson Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-2.14%
|
$693
$7.92 P/Share
|
|
Nov 14
2024
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
490
-0.15%
|
$3,430
$7.92 P/Share
|
|
Nov 14
2024
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
59,766
-2.47%
|
$418,362
$7.92 P/Share
|
|
Nov 14
2024
|
Eric Devroe Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
613
-0.9%
|
$4,291
$7.92 P/Share
|
|
Oct 17
2024
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-1.44%
|
$3,906
$7.87 P/Share
|
|
Oct 01
2024
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
284
-0.73%
|
$1,704
$6.98 P/Share
|